Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why

Core Insights - Mineralys Therapeutics, Inc. has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3] - The Zacks rating system is particularly useful for individual investors as it focuses on earnings estimate revisions rather than subjective factors that can affect Wall Street analyst ratings [2][4] Earnings Outlook - The recent upgrade reflects a positive outlook on the company's earnings, which is expected to lead to buying pressure and an increase in stock price [3][5] - The Zacks Consensus Estimate for Mineralys Therapeutics has increased by 19.6% over the past three months, indicating a favorable shift in earnings expectations [8] Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7] - The upgrade to Zacks Rank 2 places Mineralys Therapeutics in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10]